Inspira Medical Center Vineland gets state approval to perform non-emergency coronary angioplasties
Inspira's Mullica Hill hospital received health department approval for the same procedure at the start of the year. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 4, 2022 Category: Biotechnology Authors: John George Source Type: news
Two-Year Results from Onyx ONE Trial: No Difference Between Onyx DES and BioFreedom DCS
The results, consistent with the outcomes seen at one year, showed that at two years there were no differences between HBR patients on one month of DAPT who received the Onyx permanent polymer drug-eluting stent (DES), made by Medtronic, and those who received the BioFreedom polymer-free drug-coated stent (DCS), made by Biosensors. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 9, 2022 Category: Cardiology Source Type: news
CTO PCI Success Rates Rising, Registry Shows CTO PCI Success Rates Rising, Registry Shows
Updated results from a registry of chronic total occlusion percutaneous coronary angioplasty cases reports improving outcomes over the past 6 years.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 9, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Late-Breaking Data Reinforce Broad Range of Patients Benefit from Abbott's Mitral and Tricuspid Heart Valve Devices
MitraClip, manufactured by Abbott
Abbott today announced late-breaking data for MitraClip ™, the world's first transcatheter edge-to-edge repair (TEER) device, and TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device. The data reinforce the capabilities of the company's structural heart solutions for both mitral and tricuspid regurgitation (MR and TR) across a broad range of patient groups battling leaky heart valves (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 8, 2022 Category: Cardiology Source Type: news
Paclitaxel Balloons on Par With Repeat Stenting for In-Stent CTO Paclitaxel Balloons on Par With Repeat Stenting for In-Stent CTO
The incidence of long-term adverse events, however, was high with balloon angioplasty and repeat stenting, highlighting the difficulty of treating this complex patient subset.First Look (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 8, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Renal Denervation for Controlling Hypertension Featured at EuroPCR
At this year's EuroPCR meeting in Paris, the largest European conference in the field of interventional cardiology, the topic of renal denervation (RDN) resurfaced with significant positive results from several trials across devices. The bottom line was that in these sham-controlled trials, renal denervation provided an additional therapeutic avenue for those patients who are unable to control their hypertension with lifestyle changes and medications. In all the studies presented, RDN lowered blood pressures whether the patient was on or off medications. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 6, 2022 Category: Cardiology Source Type: news
Abbott recalls Dragonfly OpStar Imaging Catheter
Abbott Medical has recalled its Dragonfly OpStar Imaging Catheter because potentia...Read more on AuntMinnie.comRelated Reading:
Abbott expands MRI compatibility for Proclaim
Abbott recalls 2 coronary angioplasty catheters
FDA clears Abbott's ICD for use with MRI (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 26, 2022 Category: Radiology Source Type: news
Shockwave Medical and Genesis MedTech Obtain Regulatory Approval in China for Intravascular Lithotripsy
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, and Genesis MedTech Group announced today that they have successfully obtained approval from China ’s National Medical Products Administration (NMPA) to market and sell the Shockwave IVL System with the Shockwave C2 Coronary IVL Catheters and the Shockwave M5 and S4 Peripheral IVL Catheters in China. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 23, 2022 Category: Cardiology Source Type: news
Significantly Improved Results for Medtronic's Evolut TAVR seen in the Optimize PRO Study
At this year's EuroPCR meeting, the interim results of the Optimize PRO study of Medtronic's Evolut ™ PRO and PRO+ TAVR systems in 400 patients were presented as a Hotline Trial: permanent pacemaker rates dropped to single digits (9.2%) and the number of patients with moderate or severe paravalvular leak (PVL) was zero (78% of patients had no or only trace PVL). Moreover, the median length of ho spital stay was one day. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 22, 2022 Category: Cardiology Source Type: news
Chronic Total Occlusion PCI Is Getting Safer -- At Least Until the Pandemic
(MedPage Today) -- ATLANTA -- Percutaneous coronary intervention for chronic total occlusion (CTO PCI) has improved in success rates, but the pandemic might have impacted complication rates, a registry study showed.
Technical and procedural... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 21, 2022 Category: Cardiology Source Type: news
Intravascular Lithotripsy May Emerge as a First-Line Therapy for Calcified Lesions in Women
“Given the established safety profile of IVL and the high rates of acute and long-term adverse events in women undergoing PCI, with or without atheroablation of calcified lesions, coronary IVL is an attractive treatment option for optimizing outcomes in our female patients,” said Alexandra Lansk y, MD, FACC, FAHA, FSCAI, FESC, Professor of Medicine (Cardiology); Director of Yale Cardiovascular Clinical Research Program, Yale University School of Medicine, New Haven, Conn. “While this is the first one-year analysis of its kind for coronary IVL, the sustained benefit in MACE at one year sug gests that IVL should be con...
Source: News from Angioplasty.Org - May 20, 2022 Category: Cardiology Source Type: news
Lithotripsy Advantage in Calcified Peripheral Vessels Holds Up at 1 Year
(MedPage Today) -- ATLANTA -- Intravascular lithotripsy (IVL) beat percutaneous transluminal angioplasty (PTA) for keeping calcified peripheral artery lesions open at 1 year, the Disrupt PAD III trial showed.
Primary patency at 1 year was 80... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 19, 2022 Category: Cardiology Source Type: news
ITAL-neo Registry: Boston Scientific's ACURATE neo2 Valve Significantly Reduces Paravalvular Leak (PVL) from 1st Generation Device
The first generation TAVR exhibited a not insignificant moderate or greater paravalvular leak. By adding a taller external skirt for the newer device, the PVL was reduced from 11.2% down to 3.5%. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 19, 2022 Category: Cardiology Source Type: news
Medtronic Receives FDA Approval for Latest Generation Drug-Eluting Coronary Stent System
Design changes include increased catheter flexibility, an innovative dual-layer balloon technology and a lower crossing profile, leading to a 16% improvement in deliverability vs. the previous generation Resolute Onyx DES. Onyx Frontier offers a broad size matrix to treat more patients and is the only 2.0 mm DES available in the United States (similar to Resolute Onyx). Further, Onyx Frontier continues to provide 4.50-5.00 mm sizes that can be expanded to 6.00 mm - specifically designed to support extra-large vessels. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 13, 2022 Category: Cardiology Source Type: news
Addition of Icosapent Ethyl Cuts CV Risk in Patients With Prior PCI
THURSDAY, March 24, 2022 -- The risk for cardiovascular events is reduced in statin-treated patients with elevated triglycerides and a history of percutaneous coronary intervention (PCI) who receive icosapent ethyl, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2022 Category: Pharmaceuticals Source Type: news
